APA (7th ed.) Citation

T, S., K, K., K, M., K, F., D, I., T, T., . . . M, O. (2023). New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma. BJUI compass, 5(2), 281. https://doi.org/10.1002/bco2.298

Chicago Style (17th ed.) Citation

T, Saito, et al. "New Risk Stratification for Adjuvant Nivolumab for High-risk Muscle-invasive Urothelial Carcinoma." BJUI Compass 5, no. 2 (2023): 281. https://doi.org/10.1002/bco2.298.

MLA (9th ed.) Citation

T, Saito, et al. "New Risk Stratification for Adjuvant Nivolumab for High-risk Muscle-invasive Urothelial Carcinoma." BJUI Compass, vol. 5, no. 2, 2023, p. 281, https://doi.org/10.1002/bco2.298.